© 2014 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.Purpose: Obesity and bone metabolism are interrelated. The aim of this study is to investigate the relationship between obesity and bone markers, leptin and insulin resistance in post-menopausal osteoporosis. Material and methods: Four study groups were included in the study. Group 1 (n = 19): osteoporosis (Tscore < -2.5 at the lumbar spine and/or femoral neck) + obese; group 2 (n = 29): non-osteoporosis + obese; group 3 (n = 25): osteoporosis + non-obese and as control group (n = 14): non-osteoporosis + non-obese. The serum levels of osteoprotegerin (OPG; osteoclastogenic marker), RECEPTOR activator of nuclear factor ligand (RANKL; osteoclastic marker), tartarate resistant acid phosphatase (TRAP; osteoclastic marker), bone alkaline phosphatase (b-ALP; osteoblastic marker) and leptin were measured by ELISA. Glucose and insulin levels were analyzed by colorimetric and electrochemiluminescence methods.Results: OPG and b-ALP levels were significantly lower in group 1 compared to group 2 (P < 0.05 and P < 0.01). Comparison of group 1 with group 3 revealed significantly higher leptin levels in the former (P < 0.001). OPG, TRAP, RANKL, bone ALP were significantly lower (P < 0.001, P < 0.001, P < 0.01, P < 0.01) and leptin levels higher (P < 0.05) in group 1 compared to control group. Comparison of group 3 with control group revealed significantly lower values of OPG, RANKL, bone ALP, TRAP for the patient group (P < 0.001, P < 0.01, P < 0.01, P < 0.001). OPG, RANKL, bone ALP, TRAP levels were significantly lower (for each P < 0.01) and leptin levels were significantly higher (P < 0.05) in group 2 compared to control group.Conclusion: Osteoprotegerin, TRAP, RANKL, bone ALP and leptin levels can be used as significantmarkers in the development of osteoporosis and/or obesity in post-menopausal women.